China Medical System Holdings Ltd. engages in the production, marketing, promotion, and sale of drugs. The firm's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The firm distributes its products within domestic market and to overseas markets.
根据最新的财务报表(Form-10K),China Medical System Holdings Limited 的总资产为 $0,净损失为 $0
CHSYF 的关键财务比率是什么?
China Medical System Holdings Limited 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
China Medical System Holdings Limited 的收入按细分市场或地理位置如何划分?
China Medical System Holdings Limited 最大收入来源是 Integrated Line,在最近的收益报告中收入为 7,750,902,245。就地区而言, China 是 China Medical System Holdings Limited 的主要市场,收入为 8,906,169,113。
China Medical System Holdings Limited 是否盈利?
不,根据最新的财务报表,China Medical System Holdings Limited 的净损失为 $0